Temesgen E. Andargie

Temesgen E. Andargie

Auto-generated profile, based on publicly available information

Temesgen E. Andargie

Genomic Research Alliance for Transplantation (GRAfT) and Laboratory of Applied Precision Omics, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD; Critical Care Medicine and Pulmonary Branch, NHLBI, Bethesda, MD

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
TATemesgen E. Andargie
Temesgen E. Andargie
NTNaoko Tsuji
Naoko Tsuji
FSFayaz Seifuddin
Fayaz Seifuddin
MJMoon Kyoo Jang
Moon Kyoo Jang
PYPeter S.T. Yuen
Peter S.T. Yuen
SASean Agbor-Enoh
Sean Agbor-Enoh
INTRODUCTION: The clinical course of coronavirus 2019 (COVID-19) is heterogeneous, ranging from mild to severe multiorgan failure and death. In this study, we analyzed cell-free DNA (cfDNA) as a biomarker of injury to define the sources of tissue injury that contribute to such different trajectories. METHODS: We conducted a multicenter prospective cohort study to enroll patients with COVID-19 and collect plasma samples. Plasma cfDNA was subject to bisulfite sequencing. A library of tissue-specific DNA methylation signatures was used to analyze sequence reads to quantitate cfDNA from different tissue types. We then determined the correlation of tissue-specific cfDNA measures to COVID-19 outcomes. Similar analyses were performed for healthy controls and a comparator group of patients with respiratory syncytial virus and influenza. RESULTS: We found markedly elevated levels and divergent tissue sources of cfDNA in COVID-19 patients compared with patients who had influenza and/or respiratory syncytial virus and with healthy controls. The major sources of cfDNA in COVID-19 were hematopoietic cells, vascular endothelium, hepatocytes, adipocytes, kidney, heart, and lung. cfDNA levels positively correlated with COVID-19 disease severity, C-reactive protein, and D-dimer. cfDNA profile at admission identified patients who subsequently required intensive care or died during hospitalization. Furthermore, the increased cfDNA in COVID-19 patients generated excessive mitochondrial ROS (mtROS) in renal tubular cells in a concentration-dependent manner. This mtROS production was inhibited by a TLR9-specific antagonist. CONCLUSION: cfDNA maps tissue injury that predicts COVID-19 outcomes and may mechanistically propagate COVID-19–induced tissue injury. FUNDING: Intramural Targeted Anti–COVID-19 grant, NIH.

21 June 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
KBKatrina Bazemore
Katrina Bazemore
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung
JMJoby Mathew
Joby Mathew
MLMerte Lemma
Merte Lemma
BHBetelihim Haile
Betelihim Haile
PSPali Shah
Pali Shah
Respiratory viral infection (RVI) in lung transplant recipients (LTRs) is a risk for chronic lung allograft dysfunction (CLAD). We hypothesize that donor-derived cell-free DNA (%ddcfDNA), at the time of RVI predicts CLAD progression. We followed 39 LTRs with RVI enrolled in the Genomic Research Alliance for Transplantation for 1 year. Plasma %ddcfDNA was measured by shotgun sequencing, with high %ddcfDNA as ≥1% within 7 days of RVI. We examined %ddcfDNA, spirometry, and a composite (progression/failure) of CLAD stage progression, re-transplant, and death from respiratory failure. Fifty-nine RVI episodes, 38 low and 21 high %ddcfDNA were analyzed. High %ddcfDNA subjects had a greater median %FEV1 decline at RVI (-13.83 vs. -1.83, p = .007), day 90 (-7.97 vs. 0.91, p = .04), and 365 (-20.05 vs. 1.09, p = .047), compared to those with low %ddcfDNA and experienced greater progression/failure within 365 days (52.4% vs. 21.6%, p = .01). Elevated %ddcfDNA at RVI was associated with an increased risk of progression/failure adjusting for symptoms and days post-transplant (HR = 1.11, p = .04). No difference in %FEV1 decline was seen at any time point when RVIs were grouped by histopathology result at RVI. %ddcfDNA delineates LTRs with RVI who will recover lung function and who will experience sustained decline, a utility not seen with histopathology.

1 December 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
JGJason F. Goldberg
Jason F. Goldberg
XTXin Tian
Xin Tian
ABAnn Bon
Ann Bon
YXYifei Xu
Yifei Xu
EGEleanor Gerhard
Eleanor Gerhard
SASean Agbor-Enoh
Sean Agbor-Enoh
BACKGROUND: Heart transplant recipients with donor-specific antibodies (DSAs) have an increased risk for antibody-mediated rejection. However, many patients with graft dysfunction and DSA do not have evidence of antibody-mediated rejection by endomyocardial biopsy (EMB). METHODS: Participants from this prospective, multicenter study underwent serial EMB, echocardiogram, DSA, and donor-derived cell-free DNA evaluations. Outcomes were defined as pAMR+ (pAMR≥1) or DSA+/left ventricle (LV) dysfunction (DSA presence+LVEF drop ≥10% to an LVEF≤50%). Cox regression evaluated the association between antibody-mediated rejection categories and death or sustained (for 3 months) reduction of LVEF to <50%. RESULTS: Two hundred sixteen patients (29% women, 39% Black race, median age 55 [interquartile range, 47–62] years) had 1488 EMB, 2792 DSA, 1821 echocardiograms, and 1190 donor-derived cell-free DNA evaluations. DSAs were present in 86 patients (40%). Fourteen patients had isolated pAMR+ episodes and 8 patients had isolated DSA+/LV dysfunction episodes; 2 patients had pAMR+ and then subsequently DSA+/LV dysfunction with pAMR+. Median %dd-cfDNA was significantly higher at diagnosis of pAMR+ (0.63% [interquartile range, 0.23–2.0]; P =0.0002), or DSA+/LV dysfunction (0.40% [interquartile range, 0.36–1.24]; P <0.0001), compared with patients without these outcomes (0.01% [interquartile range, 0.0001–0.10]). Both pAMR+ and DSA+/LV dysfunction were associated with long-term clinical outcome of death (n=18) or prolonged LV dysfunction (n=10): pAMR+ (hazard ratio, 2.8 [95% CI, 1.03–7.4]; P =0.043); DSA+/LV dysfunction (hazard ratio, 26.2 [95% CI, 9.6–71.3]; P <0.001); composite of both definitions (hazard ratio, 6.5 [95% CI, 2.9–14.3]; P <0.001). Patients who developed pAMR+ or DSA+/LV dysfunction within the first 6 months of transplant were more likely to die within 3 years posttransplant (hazard ratio, 3.9 [95% CI, 1.03–14.6]; P =0.031). CONCLUSIONS: Expanding the characterization of antibody-mediated rejection to include patients with DSA and concurrent allograft dysfunction identified DSA+ patients at risk for death and prolonged LV dysfunction.

1 April 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PSPalak Shah
Palak Shah
SASean Agbor-Enoh
Sean Agbor-Enoh
BLBenjamin Seiyon Lee
Benjamin Seiyon Lee
TATemesgen E. Andargie
Temesgen E. Andargie
SSShashank S. Sinha
Shashank S. Sinha
OIon behalf of the GRAfT Investigators
on behalf of the GRAfT Investigators
BACKGROUND: Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. We hypothesized that this risk may be associated with higher levels of donor-derived cell-free DNA (dd-cfDNA) and cell-free mitochondrial DNA. METHODS: The Genomic Research Alliance for Transplantation is a multicenter, prospective, longitudinal cohort study. Sequencing was used to quantitate dd-cfDNA and polymerase chain reaction to quantitate cell-free mitochondrial DNA in plasma. AR was defined as ≥2R cellular rejection or ≥1 antibody-mediated rejection. The primary composite outcome was AR, graft dysfunction (left ventricular ejection fraction <50% and decrease by ≥10%), or death. RESULTS: We included 148 patients (65 Black patients and 83 White patients), median age was 56 years and 30% female sex. The incidence of AR was higher in Black patients compared with White patients (43% versus 19%; P =0.002). Antibody-mediated rejection occurred predominantly in Black patients with a prevalence of 20% versus 2% ( P <0.001). After transplant, Black patients had higher levels of dd-cfDNA, 0.09% (interquartile range, 0.001–0.30) compared with White patients, 0.05% (interquartile range, 0.001–0.23; P =0.003). Beyond 6 months, Black patients showed a persistent rise in dd-cfDNA with higher levels compared with White patients. Cell-free mitochondrial DNA was higher in Black patients (185 788 copies/mL; interquartile range, 101 252–422 133) compared with White patients (133 841 copies/mL; interquartile range, 75 346–337 990; P <0.001). The primary composite outcome occurred in 43% and 55% of Black patients at 1 and 2 years, compared with 23% and 27% in White patients, P <0.001. In a multivariable model, Black patient race (hazard ratio, 2.61 [95% CI, 1.35–5.04]; P =0.004) and %dd-cfDNA (hazard ratio, 1.15 [95% CI, 1.03–1.28]; P =0.010) were associated with the primary composite outcome. CONCLUSIONS: Elevated dd-cfDNA and cell-free mitochondrial DNA after heart transplant may mechanistically be implicated in the higher incidence of AR and worse clinical outcomes in Black transplant recipients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02423070.

3 May 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MKMichael B. Keller
Michael B. Keller
DNDavid Newman
David Newman
MAMuhtadi Alnababteh
Muhtadi Alnababteh
LPLucia Ponor
Lucia Ponor
PSPali Shah
Pali Shah
SASean Agbor-Enoh
Sean Agbor-Enoh

1 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TATemesgen E. Andargie
Temesgen E. Andargie
KRKaterina Roznik
Katerina Roznik
NRNeelam Redekar
Neelam Redekar
THTom Hill
Tom Hill
WZWeiqiang Zhou
Weiqiang Zhou
SASean Agbor-Enoh
Sean Agbor-Enoh
Multisystem inflammatory syndrome in children (MIS-C) is a rare but life-threatening hyperinflammatory condition induced by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes pediatric COVID-19 (pCOVID-19). The relationship of the systemic tissue injury to the pathophysiology of MIS-C is poorly defined. We leveraged the high sensitivity of epigenomics analyses of plasma cell-free DNA (cfDNA) and plasma cytokine measurements to identify the spectrum of tissue injury and glean mechanistic insights. Compared with pediatric healthy controls (pHCs) and patients with pCOVID-19, patients with MIS-C had higher levels of cfDNA primarily derived from innate immune cells, megakaryocyte-erythroid precursor cells, and nonhematopoietic tissues such as hepatocytes, cardiac myocytes, and kidney cells. Nonhematopoietic tissue cfDNA levels demonstrated significant interindividual variability, consistent with the heterogenous clinical presentation of MIS-C. In contrast, adaptive immune cell–derived cfDNA levels were comparable in MIS-C and pCOVID-19 patients. Indeed, the cfDNA of innate immune cells in patients with MIS-C correlated with the levels of innate immune inflammatory cytokines and nonhematopoietic tissue–derived cfDNA, suggesting a primarily innate immunity–mediated response to account for the multisystem pathology. These data provide insight into the pathogenesis of MIS-C and support the value of cfDNA as a sensitive biomarker to map tissue injury in MIS-C and likely other multiorgan inflammatory conditions.